Status:
ACTIVE_NOT_RECRUITING
Multivessel TALENT
Lead Sponsor:
National University of Ireland, Galway, Ireland
Conditions:
Coronary Artery Disease
Myocardial Ischemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multivessel TALENT is a prospective, randomized, multi-center study comparing clinical outcomes between SUPRAFLEX Cruz and SYNERGY in approximately 1550 patients with de-novo three vessel disease unde...
Eligibility Criteria
Inclusion
- Male or female patients' ≥18 years.
- At least 1 stenosis (angiographic, visually determined de novo lesions with ≥50% DS) in all 3 major epicardial territories (LAD and/or side branch, LCX and/or side branch, RCA and/or side branch) supplying viable myocardium without left main involvement.
- The vessel should have a reference vessel diameter ranging from ≥2.25 mm to ≤4.50 mm (no limitation on the number of treated lesions, vessels, or lesion length).
- Patients with chronic coronary syndrome or stabilized acute coronary syndromes.
- All anatomical SYNTAX Scores are eligible for initial screening with the SYNTAX Score II, provided that the SYNTAX Score II recommends equipoise risk (PCI or CABG) or PCI only.
- Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee and is willing to comply with all protocol-required evaluations.
- Agree with conditional longer follow up from 2 to 5 years with one phone contact yearly.
Exclusion
- Under the age of 18.
- Unable to give informed consent.
- Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice).
- Known contraindication to medications such as Aspirin, Heparin, Bivalirudin, Prasugrel and Ticagrelor.
- Prior PCI or prior CABG.
- Ongoing ST-elevation myocardial infarction (STEMI).
- Cardiogenic shock is also an exclusion criteria.
- Concurrent medical condition with a life expectancy of less than 2 years.
- Currently participating in another trial and not yet at its primary endpoint.
- Patient with both ostial LAD and ostial LCX stenosis, or left main stenosis.
- Previous intracranial haemorrhage.
Key Trial Info
Start Date :
September 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
1550 Patients enrolled
Trial Details
Trial ID
NCT04390672
Start Date
September 22 2020
End Date
September 1 2026
Last Update
October 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NUIG
Galway, Ireland, H91 TK33